MarketCap
Facebook
X
Telegram
Sorrento Therapeutics Financial Ratios 2022-2006 | SRNE
Brief overview of Sorrento Therapeutics's valuation multiples
This overview follows the five latest available observations from 2017 through 2021.
Market valuation is represented by EV/EBITDA 27.67x (median 2.95x), P/S 14.1x (median 31.1x), P/B 9.55x (median 8.79x). The multiple basket looks neutral against its history, differing from median levels by roughly +8.6%.
The latest available business-quality ratios are ROE 30.8%, ROA -121.1%, ROCE 27.1%. The business is not generating positive returns on invested resources. Valuation should be read cautiously until earnings recover.
The time from paying for inputs to receiving cash rose from -379.3 days to 125.4 days. Cash turnover slowed.
Conclusion
Sorrento Therapeutics's multiples form a balanced picture without a clear discount or premium. Future appeal depends on earnings and return trends.
Annual Financial Ratios Sorrento Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
- | -1.7 | -7.4 | -1.0 | -1.1 | 76.0 | -4.3 | -4.9 | -9.9 | -7.9 | -0.0 | -790.3 | - | - | - | - | - |
P/S |
- | 14.1 | 55.6 | 22.1 | 31.1 | 34.0 | 65.2 | 48.6 | 90.1 | 376.8 | 0.1 | 4833.6 | - | - | - | - | - |
EPS |
-1.4 | -1.4 | -1.3 | -2.2 | -1.9 | 0.1 | -1.2 | -1.2 | -1.3 | -1.5 | -0.4 | -0.0 | -0.0 | - | - | - | - |
EV (Enterprise Value) |
471 M | 1.33 B | 2.56 B | 790 M | 473 M | 899 M | 495 M | 386 M | 306 M | 167 M | -4.45 M | 2.55 B | -5.28 M | -3.43 M | - | - | - |
EBITDA per Share |
-1.17 | -1.32 | -1.02 | -1.87 | -1.33 | 0.47 | -1.86 | -1.94 | -1.18 | -1.35 | -400 | -0.01 | -0.01 | - | - | - | - |
EV/EBITDA |
-1.0 | -3.4 | -11.0 | -3.2 | -3.4 | 27.7 | -5.3 | -5.4 | -9.7 | -8.2 | 1.0 | -828.6 | 3.0 | - | - | - | - |
PEG |
- | 0.02 | 0.07 | 0.01 | 0.01 | -2.14 | -0.0 | -0.0 | -0.71 | 0.04 | 0.15 | 0.57 | - | - | - | - | - |
P/B |
- | 9.5 | 15.8 | 8.8 | 1.0 | 3.4 | 3.0 | 1.6 | 3.2 | 2.6 | 0.0 | 607.6 | - | - | - | - | - |
P/CF |
- | -2.6 | -13.9 | -1.7 | -1.9 | -7.0 | -3.7 | -5.3 | -9.2 | -10.5 | -0.0 | -932.4 | - | - | - | - | - |
ROE % |
3078.97 | -543.92 | -180.72 | -371.64 | -97.17 | 4.58 | -76.12 | -31.56 | -31.88 | -32.80 | -78.18 | -76.89 | -35.57 | -29.44 | 21.92 | 17.78 | 100.53 |
ROA % |
-121.15 | -61.65 | -55.70 | -52.38 | -32.61 | 2.12 | -15.17 | -13.34 | -24.49 | -23.67 | -71.44 | -70.84 | -31.79 | - | - | - | - |
ROCE % |
2710.64 | -509.79 | -52.72 | -53.13 | -26.65 | 7.33 | -30.33 | -23.36 | -26.32 | -24.88 | -78.30 | -77.04 | -35.65 | - | - | - | - |
Current Ratio |
1.0 | 1.1 | 1.4 | 1.1 | 1.5 | 1.9 | 1.3 | 1.7 | 4.3 | 3.6 | 11.6 | 12.7 | - | - | - | - | - |
DSO |
125.4 | 118.1 | 136.7 | 256.1 | 159.2 | 34.9 | 118.0 | 65.0 | 53.7 | 188.0 | 24.9 | 42.2 | - | - | - | - | - |
DIO |
- | - | 67.2 | 100.3 | 74.9 | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | 907.2 | 824.1 | 613.4 | 841.6 | 2165.0 | 280.3 | 340.3 | 118284.3 | - | - | - | - | - | - | - |
Operating Cycle |
125.4 | 118.0 | 204.0 | 356.3 | 234.1 | 34.9 | 118.0 | 65.0 | 53.7 | 188.0 | 24.9 | 42.2 | - | - | - | - | - |
Cash Conversion Cycle |
125.4 | 118.0 | -703.2 | -467.8 | -379.3 | -806.7 | -2047.0 | -215.3 | -286.5 | -118096.4 | 24.9 | 42.2 | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Sorrento Therapeutics
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.17 | -0.26 | - | -0.2 | -0.54 | -0.12 | -0.47 | -0.4 | -0.57 | 0.01 | -0.27 | -0.33 | -0.36 | -0.36 | -0.41 | -0.49 | -0.46 | -0.88 | -0.41 | -0.4 | -0.73 | -0.38 | 0.6 | -0.03 | -0.2 | -0.45 | -0.3 | 0.22 | -0.97 | -0.48 | -0.62 | -0.03 | -0.3 | -0.29 | -0.26 | -0.27 | -0.33 | -0.44 | - | -0.24 | -0.35 | -0.01 | - | -0.1 | -0.08 | - | - | - | - | - |
EBITDA per Share |
-0.13 | -0.19 | - | -0.22 | -0.28 | -0.31 | - | -0.31 | -0.33 | -0.29 | - | -0.3 | -0.19 | -0.22 | - | -0.34 | -0.36 | -0.98 | - | -0.36 | -0.24 | -0.36 | - | 1.33 K | -146 | -430 | - | -189 | -0.97 | -0.64 | - | -0.91 | -251 | -258 | - | -0.17 | -0.25 | -0.39 | - | -0.19 | -0.33 | -0.01 | - | -0.09 | -0.07 | - | - | - | - | - |
ROE % |
-75.97 | -140.40 | -251.65 | -435.04 | -458.21 | -382.01 | -362.91 | -222.81 | -172.61 | -139.74 | -205.34 | -241.98 | -341.44 | -352.77 | -370.15 | -313.98 | -194.98 | -156.07 | -88.03 | -39.99 | -20.81 | -7.12 | -33.16 | -79.75 | -59.54 | -75.79 | -55.27 | -51.28 | -69.96 | -50.37 | -41.41 | -30.91 | -40.98 | -39.81 | -46.43 | -49.48 | -120.86 | -134.46 | -117.40 | -134.29 | -134.51 | -79.03 | -54.60 | -79.34 | -93.78 | -98.95 | -72.34 | -24.74 | -31.34 | -16.26 |
ROA % |
-100.35 | -84.27 | -53.93 | -74.71 | -76.08 | -62.86 | -57.68 | -50.24 | -48.28 | -41.47 | -54.03 | -51.96 | -49.48 | -44.57 | -50.15 | -46.86 | -43.43 | -50.08 | -39.80 | -20.60 | -13.01 | -0.38 | 0.40 | -15.27 | -9.66 | -18.77 | -18.80 | -22.10 | -27.54 | -23.00 | -24.23 | -22.50 | -29.52 | -28.93 | -32.11 | -34.94 | -88.45 | -101.47 | -90.33 | -106.06 | -107.80 | -71.31 | -50.63 | -71.85 | -84.03 | -88.44 | -64.11 | -21.21 | -27.92 | -14.98 |
ROCE % |
-50.27 | -135.10 | -219.84 | -296.94 | -267.94 | -214.98 | -167.80 | -208.25 | -165.91 | -154.62 | -117.93 | -234.03 | -253.87 | -312.46 | -269.74 | -291.36 | -186.42 | -139.98 | -46.63 | 55.38 | 62.44 | 33.22 | 47.08 | 29.80 | -104.80 | -116.35 | -75.98 | -100.35 | -94.62 | -72.20 | -46.10 | -56.14 | -42.01 | -47.16 | -36.98 | -47.69 | -119.40 | -133.51 | -116.82 | -133.74 | -134.15 | -79.05 | -54.69 | -79.48 | -93.95 | -99.13 | -72.47 | -24.79 | -31.39 | -16.30 |
Current Ratio |
0.7 | 0.8 | 1.0 | 1.3 | 1.3 | 1.4 | 1.1 | 1.2 | 1.3 | 1.6 | 1.4 | 1.3 | 1.2 | 1.1 | 1.1 | 1.0 | 1.1 | 1.2 | 1.5 | 1.6 | 2.3 | 2.2 | 1.9 | 1.3 | 1.3 | 1.2 | 1.3 | 1.4 | 1.6 | 1.5 | 1.7 | 1.8 | 3.2 | 0.7 | 4.3 | 3.2 | 3.4 | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
179.9 | 143.2 | - | 128.2 | 196.6 | 107.7 | 122.7 | 147.1 | 130.8 | 101.8 | 120.1 | 110.9 | 120.7 | 144.6 | 91.1 | 168.6 | 121.1 | 83.5 | 40.2 | 49.8 | 71.3 | 44.7 | 8.7 | 1.5 | 46.1 | 37.8 | 25.2 | 28.3 | 101.8 | 94.6 | 52.0 | 62.9 | 65.4 | 70.8 | 98.2 | 55.9 | 72.6 | 49.1 | - | 429.1 | 253.9 | 161.2 | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 155.7 | 147.6 | - | 121.5 | 215.7 | 100.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 549.8 | 562.8 | - | 568.9 | 705.4 | 658.6 | - | 951.4 | 1188.0 | 852.9 | - | 633.1 | 1169.5 | 569.1 | - | 309.2 | 633.5 | 317.5 | - | 238.6 | 218.4 | 269.6 | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | 143.2 | - | 35988.6 | 31296.8 | 107.7 | 122.7 | 10819.5 | -80353.9 | -3464.3 | 123.0 | -2499.9 | -301.1 | -2458.5 | 91.1 | 168.6 | 214.6 | 207.2 | 40.2 | 189.4 | 305.1 | 145.0 | 9.9 | 1.6 | 43.2 | 36.6 | 38.5 | 69.0 | 171.6 | 120.0 | 61.6 | 74.7 | 70.2 | 76.3 | 83.7 | 52.4 | 86.2 | 52.6 | - | 433.2 | 253.2 | 161.3 | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | 143.2 | - | 35988.6 | 31296.8 | 107.7 | 122.7 | 10819.5 | -80353.9 | -3464.3 | 123.0 | -2499.9 | -301.1 | -2458.5 | 91.1 | 168.6 | -553.8 | -612.1 | 40.2 | -389.8 | -723.3 | -680.8 | 9.9 | -831.9 | -1065.1 | -743.6 | 38.5 | -1739.0 | -2390.2 | -1102.7 | 61.6 | -127.6 | -318.9 | -192.1 | 83.7 | -234.4 | -210.1 | -256.0 | - | 433.2 | 253.2 | 161.3 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Sorrento Therapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Niderland
Irlanda
